ArticleThe journal of pathology. Clinical research2015
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.
Article in The journal of pathology. Clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Clinicopathological characterization of cervical squamous cell carcinoma withOncology letters · 2026Article
- Comprehensive Genomic Characterization of 102 Cervical Adenocarcinoma Tumors.Medicina (Kaunas, Lithuania) · 2026Article
- Context is key: how diagnostic and prognostic markers are reshaping gynecologic pathology.The journal of pathology. Clinical research · 2025Review
- HPV-Independent Cervical Cancer-A New Challenge of Modern Oncology.International journal of molecular sciences · 2025Review
- Molecular Features of HPV-Independent Cervical Cancers.Pathogens (Basel, Switzerland) · 2025Review
- A comparative analysis of somatic mutational profiles according to HIV status among women with cervical intraepithelial neoplasia 3 (CIN3): a focus on hotspots in TP53, PIK3CA, PTEN, and EGFR.Infectious agents and cancer · 2025Article
- Intratumor heterogeneity of HPV integration in HPV-associated head and neck cancer.Nature communications · 2025Article
- Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.Molecular biomedicine · 2024Review
- The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma.Frontiers in molecular biosciences · 2021Review
- Metabolism-Relevant Molecular Classification Identifies Tumor Immune Microenvironment Characterization and Immunotherapeutic Effect in Cervical Cancer.Frontiers in molecular biosciences · 2021Article
- Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice.Cancer science · 2020Article
- The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications.Cancer medicine · 2018Review
- The molecular landscape of head and neck cancer.Nature reviews. Cancer · 2018Review
- Article
- Detection of circulating tumor cells in cervical cancer using a conditionally replicative adenovirus targeting telomerase-positive cells.Cancer science · 2018Article
- Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Somatic Host Cell Alterations in HPV Carcinogenesis.Viruses · 2017Review
- Gynaecological cancer: Novel molecular subtypes of cervical cancer - potential clinical consequences.Nature reviews. Clinical oncology · 2017Article
- Molecular events leading to HPV-induced high grade neoplasia.Papillomavirus research (Amsterdam, Netherlands) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Somatic mutations in cervical intraepithelial neoplasia (CIN) are largely unknown. Here, we profiled 35 cervical carcinomas and 23 CIN grade 2/3 (CIN2/3) for mutations in 48 cancer-related genes using a Next Generation Sequencing-based cancer panel. PIK3CA exon 9 was the most frequently mutated locus in cervical carcinoma and the only mutated locus detected in CIN2/3. These PIK3CA exon 9 mutation findings were verified in a large, independent series (n = 647) covering all stages of cervical carcinogenesis using high resolution melting-guided Sanger sequencing. PIK3CA exon 9 mutation frequency was 37.1% (13/35; 95%CI 21.2-54.0%) in cervical carcinoma, and 2.4% (5/209; 95%CI 0.5-4.7%) in CIN3. No PIK3CA exon 9 mutations were detected in CIN2 (0/144), CIN1 (0/154) and normal cervix (0/105). In a third series of 46 CIN2/3 lesions from women with a known 5-year history of preceding high-risk human papillomavirus (hrHPV) infection, detection of PIK3CA exon 9 mutation was confined to 2 (5.4%; 95%CI 0.0-13.2%) CIN3 lesions with preceding hrHPV infection ≥5 years, and was absent in those with a short duration (<5 years) of preceding hrHPV infection. In conclusion, somatic mutation in PIK3CA represents a late event during cervical carcinogenesis, detected in a substantial subset of cervical carcinoma, but only in a minority of CIN3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.